What is Zacks Research’s Estimate for AbbVie Q1 Earnings?

AbbVie Inc. (NYSE:ABBV) – Investment analysts at Zacks Research raised their Q1 2026 earnings estimates for AbbVie in a research note issued to investors on Wednesday, January 14th. Zacks Research analyst Team now expects that the company will post earnings per share of $3.01 for the quarter, up from their prior estimate of $2.94. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie’s Q2 2026 earnings at $3.71 EPS, Q3 2026 earnings at $3.76 EPS, FY2026 earnings at $14.18 EPS, Q1 2027 earnings at $3.27 EPS, Q2 2027 earnings at $4.03 EPS, Q3 2027 earnings at $4.30 EPS and FY2027 earnings at $15.75 EPS.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS.

A number of other equities analysts have also commented on ABBV. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Citigroup dropped their price target on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Guggenheim lifted their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price target on shares of AbbVie in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $247.84.

AbbVie Price Performance

AbbVie stock opened at $214.38 on Friday. AbbVie has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The firm’s 50 day simple moving average is $226.80 and its 200-day simple moving average is $216.47. The company has a market cap of $378.89 billion, a P/E ratio of 162.41, a price-to-earnings-growth ratio of 0.88 and a beta of 0.36.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Hedge Funds Weigh In On AbbVie

A number of institutional investors have recently modified their holdings of the company. Conning Inc. grew its holdings in AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock worth $35,458,000 after purchasing an additional 12,690 shares during the last quarter. Diversified Trust Co boosted its position in shares of AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock worth $13,215,000 after purchasing an additional 10,891 shares in the last quarter. Dohj LLC grew its stake in AbbVie by 41.8% during the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock worth $802,000 after buying an additional 1,335 shares during the last quarter. Permanent Capital Management LP acquired a new position in AbbVie during the 3rd quarter valued at about $720,000. Finally, Railway Pension Investments Ltd raised its stake in AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after buying an additional 211,800 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.